# A Phase 1 Study of ADI-001 in B Cell Malignancies

> **NCT04735471** · PHASE1 · TERMINATED · sponsor: **Adicet Therapeutics** · enrollment: 34 (actual)

## Conditions studied

- Lymphoma, Follicular
- Lymphoma, Mantle-Cell
- Marginal Zone Lymphoma
- Primary Mediastinal B-cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Lymphoma, Non-Hodgkin

## Interventions

- **GENETIC:** ADI-001
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04735471
- **Lead sponsor:** Adicet Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-04
- **Primary completion:** 2025-02-03
- **Final completion:** 2025-02-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Terminated - Halted Prematurely
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735471, "A Phase 1 Study of ADI-001 in B Cell Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04735471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*